Article info
PDFSystemic sclerosis
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial
- Correspondence to Dr Dinesh Khanna, Division of Rheumatology, University of Michigan, Ann Arbor, MI 48109, USA; khannad{at}med.umich.edu; Dr Oliver Distler, Department of Rheumatology, University Hospital Zurich, 8091 Zurich, Switzerland; oliver.distler{at}usz.ch
Citation
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial
Publication history
- Received December 13, 2019
- Revised February 19, 2020
- Accepted March 9, 2020
- First published April 15, 2020.
Online issue publication
April 15, 2020
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.